Back to top
more

Dr. Reddys Laboratories (RDY)

(Real Time Quote from BATS)

$79.23 USD

79.23
11,544

-1.21 (-1.50%)

Updated Jul 16, 2024 10:10 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (168 out of 250)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zacks.com featured highlights include Caterpillar, Applied Materials, Toll Brothers, Walmart and Dr. Reddy's Laboratories

by Zacks Equity Research

Caterpillar, Applied Materials, Toll Brothers, Walmart and Dr. Reddy's Laboratories are part of the Zacks Screen of the Week article.

Zacks.com featured highlights include Trip.com, Dr. Reddy's Laboratories, J&J Snack Foods and Granite Ridge Resources

by Zacks Equity Research

Trip.com, Dr. Reddy's Laboratories, J&J Snack Foods and Granite Ridge Resources are part of the Zacks Screen of the Week article.

Sweta Killa headshot

5 Dividend Growth Stocks to Buy in a Weak Market

by Sweta Killa

Caterpillar (CAT), Applied Materials (AMAT), Toll Brothers (TOL), Walmart (WMT) and Dr. Reddy's (RDY) could be solid choices for investors amid market weakness.

Nilanjan Banerjee headshot

Buy These 4 Low-Beta Stocks to Sail Through the Choppy Market

by Nilanjan Banerjee

It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Trip.com (TCOM), Dr. Reddy's (RDY), J&J Snack (JJSF) and Granite Ridge (GRNT) are poised to gain.

TEVA to Pay $225 Million to Settle Price-Fixing Charges (Revised)

by Zacks Equity Research

TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5 million will be due each year from 2024 through 2027 and $135 million will become due in 2028.

TEVA to Pay $250 Million to Settle Price-Fixing Charges

by Zacks Equity Research

TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5 million will be due each year from 2024 through 2027 and $135 million will become due in 2028.

Here's Why You Should Add Dr. Reddy's (RDY) to Your Portfolio

by Zacks Equity Research

Dr. Reddy's (RDY) continues to enjoy a strong foothold in the global generics market due to its deep generic drugs pipeline. The company is also looking to strengthen its biosimilars portfolio.

Nilanjan Choudhury headshot

5 Growth Opportunities Thriving on Relative Price Strength

by Nilanjan Choudhury

HURN, EHC, RDY, BOOM and HWKN are five stocks with explosive relative price strength.

Vaishali Doshi headshot

Add These 4 Top-Performing Liquid Stocks for Strong Returns

by Vaishali Doshi

Here are four top-ranked liquid stocks, Dr. Reddy's (RDY), Surmodics (SRDX), Fluor Corporation (FLR) and GigaCloud Technology (GCT), which investors can add to their portfolio for solid gains.

Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Dr. Reddy's Laboratories and Teva Pharmaceutical

by Zacks Equity Research

Amphastar Pharmaceuticals, Dr. Reddy's Laboratories and Teva Pharmaceutical are part of the Zacks Industry Outlook article.

Sundeep Ganoria headshot

3 Generic Drug Stocks to Watch Amid Improving Market Prospects

by Sundeep Ganoria

The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to AMPH, RDY and TEVA.

Zacks.com featured highlights Caterpillar, Walmart, KB Home, Progress Software and Dr. Reddy's

by Zacks Equity Research

Caterpillar, Walmart, KB Home, Progress Software and Dr. Reddy's have been highlighted in this Screen of The Week article.

Dr. Reddy's Laboratories Ltd (RDY) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Doctor Reddy's (RDY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Sweta Killa headshot

5 Dividend Growth Stocks for Safe and Stable Returns

by Sweta Killa

Caterpillar (CAT), Walmart (WMT), KB Home (KBH), Progress Software (PRGS) and Dr. Reddy's (RDY) could be solid choices for your portfolio.

Zacks.com featured highlights Trip.com, Dr. Reddy's, Sterling Check and MINISO Group

by Zacks Equity Research

Trip.com, Dr. Reddy's, Sterling Check and MINISO Group have been highlighted in this Screen of The Week article.

Nilanjan Banerjee headshot

Buy These 4 Low-Beta Stocks to Counter the Choppy Market

by Nilanjan Banerjee

It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Trip.com (TCOM), Dr. Reddy's (RDY), Sterling Check (STER) and MINISO Group (MNSO) are poised to gain.

TEVA Q2 Earnings & Sales Top as Austedo Outperforms, Stock Up

by Zacks Equity Research

TEVA's second-quarter results were strong as it beat estimates for earnings as well sales.

Dr. Reddy's (RDY) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Dr. Reddy's (RDY) reports better-than-expected fiscal first-quarter 2024 results.

Journey Medical (DERM) to Post Skin Disease Data, Stock Rises 26%

by Zacks Equity Research

Journey Medical (DERM) rises 26% on Monday after announcing the tentative date for reporting top-line results from its late-stage studies evaluating DFD-29 in treating papulopustular rosacea.

Journey Medical (DERM) Up on Rosacea Candidate's Positive Data

by Zacks Equity Research

Journey Medical's (DERM) phase I study, assessing the impact of DFD-29 on the microbial flora of healthy adults, obtains its primary endpoints.

Dr. Reddy's (RDY) Meets Goals in Actemra Biosimilar Study

by Zacks Equity Research

Dr. Reddy's (RDY) announces meeting primary and secondary endpoints in the phase I study of its proposed tocilizumab biosimilar for the treatment of rheumatoid arthritis in adults.

Zacks Industry Outlook Highlights Amphastar, Dr. Reddy's and Teva Pharmaceutical

by Zacks Equity Research

Amphastar, Dr. Reddy's and Teva Pharmaceutical have been highlighted in this Industry Outlook article.

Sundeep Ganoria headshot

3 Generic Drug Stocks to Watch Amid Macro Headwinds

by Sundeep Ganoria

The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.

ARS Pharma (SPRY) Gets FDA Panel Vote for Epinephrine Nasal Spray

by Zacks Equity Research

ARS Pharmaceuticals (SPRY) gains as it gets favorable votes from the FDA advisory committee for epinephrine spray to treat severe allergic reactions.

Dr. Reddy's (RDY) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Dr. Reddy's (RDY) reports better-than-expected fourth-quarter results where both earnings and revenues beat estimates.